Drugs that contain Dexamethasone
1. Dextenza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(4 months from now) | |
| US8563027 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
Feb, 2030
(5 years from now) | |
| US8409606 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
May, 2030
(6 years from now) | |
| US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-876) | Oct 07, 2024 |
| New Indication(I-800) | Jun 20, 2022 |
| New Product(NP) | Nov 30, 2021 |
Market Authorisation Date: 30 November, 2018
Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular inflammation and pain following ophthalmic surgery
Dosage: INSERT;OPHTHALMIC
DEXTENZA family patents
2. Dexycu Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7560120 | EYEPOINT PHARMS | Vehicles for delivery of biologically active substances |
Sep, 2022
(1 year, 7 months ago) | |
| US6960346 | EYEPOINT PHARMS | Vehicles for delivery of biologically active substances |
Jul, 2023
(9 months ago) | |
| US10799642 | EYEPOINT PHARMS | Dose guides for injection syringe |
May, 2032
(8 years from now) | |
| US10159683 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(10 years from now) | |
| US10028965 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(10 years from now) | |
| US10022502 | EYEPOINT PHARMS | Dose guides for injection syringe |
Jun, 2034
(10 years from now) | |
| US11097061 | EYEPOINT PHARMS | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2021 |
Market Authorisation Date: 09 February, 2018
Treatment: Treatment of postoperative inflammation; A method of loading medication into a syringe and delivering the medication to a treatment site
Dosage: SUSPENSION;INTRAOCULAR
DEXYCU KIT family patents
3. Hemady patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10537585 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
| US11304961 | DEXCEL | Compositions comprising dexamethasone |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-271) | Oct 03, 2026 |
Market Authorisation Date: 03 October, 2019
Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product
Dosage: TABLET;ORAL
HEMADY family patents
4. Ozurdex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7033605 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US8088407 | ABBVIE | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US6726918 | ABBVIE | Methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US9012437 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US9283178 | ABBVIE | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US8043628 | ABBVIE | Methods for reducing edema |
Oct, 2020
(3 years ago) | |
| US9775849 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US8063031 | ABBVIE | Implants and methods for treating inflammation-mediated conditions of the eye |
Oct, 2020
(3 years ago) | |
| US9592242 | ABBVIE | Methods for treating edema in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US7767223 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use |
Nov, 2021
(2 years ago) | |
| US10702539 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US9192511 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US8034370 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US8506987 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US8034366 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US10076526 | ABBVIE | Ocular implant made by a double extrusion process |
Jan, 2023
(1 year, 3 months ago) | |
| US6899717 | ABBVIE | Methods and apparatus for delivery of ocular implants |
Nov, 2023
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 17, 2012 |
| New Indication(I-686) | Jun 29, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 24, 2017 |
Market Authorisation Date: 17 June, 2009
Treatment: Treatment of macular edema; Intravitreal treatment of diabetic macular edema; Treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of uveitis; Delivering an ocular...
Dosage: IMPLANT;INTRAVITREAL
OZURDEX family patents